Inivata Appoints Dr. Alan Schafer as Chief Technology Officer
Inivata, a leader in liquid biopsy, today announces the appointment of Dr. Alan Schafer as Chief Technology Officer (CTO), effective immediately. Alan will lead the development of Inivata’s leading InVision® liquid biopsy technology platform and new product development.
Alan brings to the role over 25 years of genetics and molecular diagnostics experience. He was previously CEO of 14M Genomics, a cancer molecular diagnostics company, and prior to that served as CEO of Population Genetics Technologies, a business specialising in infectious disease diagnostics and next-generation sequencing technologies. Earlier roles include those of Global VP Technology Development at GlaxoSmithKline and VP Genetics at Incyte. More recently, Alan has worked as an independent consultant for the biotechnology industry, academia and the investment community, offering his expertise in genomic and biology technologies with a particular focus on the interface between science and technology and business. Alan holds a PhD from the University of Southern California and has authored numerous publications in the molecular genetics field.
Clive Morris, Chief Executive Officer of Inivata, commented:
“Alan’s appointment to the leadership team reflects our commitment to continuing to advance our cutting-edge liquid biopsy technology platform. He brings a wealth of experience in molecular diagnostics which will help to ensure that we remain at the forefront of innovation in the space as we drive the platform closer to patients in need.”
Alan Schafer, Chief Technology Officer of Inivata, commented:
Inivata’s pioneering technology offers the potential to transform the lives of cancer patients, and it is a very exciting time to join the company as it rolls out the RaDaR assay for the detection of residual disease and recurrence. This is clearly a key area of focus for potential biopharma partners and I look forward to working with the rest of the executive team to drive forward Inivata’s strategy.